Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Eyes and Vision

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 100%High 0 · 0%

Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every 4 weeks showed no clear difference in adverse events at ≥ 12 months compared with placebo (moderate certainty).

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
RR 1.07 [0.66, 1.73]
1 study · 30 participants
Moderate

Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
RR 1.06 [0.98, 1.16]
1 study · 151 participants
Moderate

Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
RR 1.02 [0.96, 1.09]
1 study · 150 participants
Moderate

Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
RR 1.04 [0.94, 1.15]
1 study · 100 participants
Moderate

Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
RR 1 [0.92, 1.08]
1 study · 99 participants
Moderate